Lee Jungnam, Jeong Seok, Lee Don Haeng, Lim Jung-Hyun, Kobayashi Makoto, Takenaka Mamoru, Kwon Chang-Il
Division of Gastroenterology, Department of Internal Medicine, Inha University Hospital, Inha University College of Medicine, Incheon, Republic of Korea.
Utah-Inha DDS and Advanced Therapeutics Research Center, Incheon, Republic of Korea.
Dig Dis Sci. 2025 Mar;70(3):1215-1222. doi: 10.1007/s10620-024-08810-1. Epub 2025 Jan 24.
Stent placement for biliary drainage in patients with malignant hilar biliary obstruction (MHBO) has been a topic of long-standing debate, and the best approach remains controversial. Therefore, we aimed to evaluate the efficacy, safety, and removability of multi-hole fully covered self-expandable metal stents (MH-FCSEMSs) in a preclinical experiment using swine hilar bile duct obstruction (HBDO) models and to assess the feasibility and safety of stent placement in patients with MHBO.
Three minipigs underwent endoscopic retrograde cholangiopancreatography (ERCP)-guided endobiliary-radio frequency ablation (EB-RFA) to establish Bismuth type II hilar bile duct stenosis models. Four weeks after EB-RFA, 10-mm diameter and 4-cm length MH-FCSEMSs were endoscopically inserted into the left intrahepatic bile duct of the models. Stent patency and migration, as well as adverse events including cholangitis and endoscopic stent removability, were assessed three months after stent placement. Additionally, clinical applications of MH-FCSEMS were performed in two patients with MHBO to determine feasibility, safety, and stent patency.
MH-FCSEMSs were successfully inserted into the left main intrahepatic bile duct and common hepatic duct of the models under ERCP in all three animals without any technical difficulties. Cholangiograms performed 12 weeks after MH-FCSEMS placement showed no stent migration, and all were successfully removed from the animal models. The functional success rate, defined as a decrease in serum total bilirubin level of more than 50% at 12 weeks after stent placement, was 100%. Moreover, MH-FCSEMSs were successfully inserted in two patients with hilar cholangiocarcinoma. The procedures were technically feasible, and no major periprocedural complications were noted.
The preliminary long-term results of both preclinical and clinical pilot studies suggest that endoscopic biliary drainage using MH-FCSEMS may be a safe and effective treatment option for stenting and stent revision in the management of HBDO. Further studies comparing clinical outcomes to those of MH-FCSEMS without multi-hole in malignant hilar biliary obstruction will be needed to verify the clinical benefits.
恶性肝门部胆管梗阻(MHBO)患者行胆管引流支架置入术一直是长期争论的话题,最佳方法仍存在争议。因此,我们旨在通过猪肝门部胆管梗阻(HBDO)模型的临床前实验评估多孔全覆膜自膨式金属支架(MH-FCSEMS)的疗效、安全性及可取出性,并评估MHBO患者支架置入的可行性和安全性。
对3只小型猪进行内镜逆行胰胆管造影(ERCP)引导下的胆管内射频消融(EB-RFA),以建立Bismuth II型肝门部胆管狭窄模型。EB-RFA术后4周,将直径10mm、长度4cm的MH-FCSEMS经内镜插入模型的左肝内胆管。在支架置入后3个月评估支架通畅情况、移位情况以及包括胆管炎和内镜下支架可取出性在内的不良事件。此外,对2例MHBO患者进行了MH-FCSEMS的临床应用,以确定其可行性、安全性和支架通畅情况。
在所有3只动物中,MH-FCSEMS均在ERCP引导下成功插入模型的左肝内主胆管和肝总管,无任何技术困难。MH-FCSEMS置入12周后进行的胆管造影显示无支架移位,且均成功从动物模型中取出。支架置入后12周血清总胆红素水平下降超过50%定义为功能成功率,为100%。此外,MH-FCSEMS成功插入2例肝门部胆管癌患者体内。手术在技术上可行,未观察到重大围手术期并发症。
临床前和临床初步研究的初步长期结果表明,使用MH-FCSEMS进行内镜胆管引流可能是HBDO治疗中支架置入和支架翻修的一种安全有效的治疗选择。需要进一步研究比较恶性肝门部胆管梗阻中MH-FCSEMS与无孔支架的临床结果,以验证其临床益处。